Q1 2022 Financial Results Call and Webcast 5/16/22 | ACRX Message Board Posts


AcelRx Pharmaceuticals, Inc.

  ACRX website

ACRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  334 of 345  at  5/13/2022 4:03:26 PM  by

Warthogdriver


 In response to msg 333 by  joephlibeetz
view thread

Re: Q1 2022 Financial Results Call and Webcast 5/16/22

Nothing has changed for me... I continue to purchase additional shares (when I have some extra cash) at this reduced price.  I see only positive catalysts in the future (DoD, increasing formulary approvals, Niyad sales, DSUVEO sales in the EU, Aguettant pre-filled syringe FDA approval in the US, etc.).  The critical metric is sales.  The lack thereof is what I believe is driving the plunge in stock price. 80% of analysts believe ACRX is a BUY.  The others are NEUTRAL.  Avg price target is $4.00/share which at the current .20c/sh is 2000% upside.
 
All the best
 
"ACRX is my TSLA" 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
335 Re: Q1 2022 Financial Results Call and Webcast 5/16/22 joephlibeetz 1 5/13/2022 6:38:15 PM




Financial Market Data provided by
.
Loading...